Shares in Avacta Group PLC (AIM:AVCT) jumped 10% after it announced the opening of two initial sites for its early-stage cancer trial.
Phase I evaluations of AVA6000, its lead pre|CISION drug candidate for soft tissue sarcoma treatment, will take place at the Memorial Sloan Kettering Cancer Center in New York and the Fred Hutch Cancer Center in Seattle.
The stock, up 95% in the year to date, jumped 12.18p on Thursday to 134.18p, valuing the business at £365mln.